Atea Pharmaceuticals Inc. (AVIR) News

Atea Pharmaceuticals Inc. (AVIR): $7.10

-0.21 (-2.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AVIR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter AVIR News Items

AVIR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AVIR News Highlights

  • For AVIR, its 30 day story count is now at 11.
  • Over the past 25 days, the trend for AVIR's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • DRUG, GOLD and ACT are the most mentioned tickers in articles about AVIR.

Latest AVIR News From Around the Web

Below are the latest news stories about Atea Pharmaceuticals Inc that investors may wish to consider to help them evaluate AVIR as an investment opportunity.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 28, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Monday, February 28, 2022 at 4:30 p.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2021, and to provide a business update. To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least f

Yahoo | February 22, 2022

Atea Pharmaceuticals (AVIR) Receives a Hold from Leerink Partners

Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Atea Pharmaceuticals (AVIR – Research Report) today and set a price target of $10.00. The company's shares closed last Tuesday at $6.42, close to its 52-week low of $6.02. According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Aligos Therapeutics. Currently, the analyst consensus on Atea Pharmaceuticals is a Hold with an average price target of $9.33.

Brian Anderson on TipRanks | February 16, 2022

8 Biotech Stocks So Cheap That Their Technology Is Effectively Free

The beleaguered sector is showing no real signs of recovery. That could spell an opportunity for some stocks.

Yahoo | February 16, 2022

10 New Stock Picks of Billionaire Rob Citrone

In this article, we discuss 10 new stock stock picks of billionaire Rob Citrone. If you want to skip our detailed analysis of these stocks, go directly to 5 New Stock Picks of Billionaire Rob Citrone. Rob Citrone is an American hedge fund manager who in 1999 co-founded Discovery Capital Management, a hedge fund that […]

Yahoo | February 14, 2022

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Yahoo | February 11, 2022

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

Pharmaceutical Research Leader Brings More Than 25 Years of Drug Discovery and Development Experience from MerckBOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President

Yahoo | February 10, 2022

Atea Pharmaceuticals to Present at 11th Annual SVB Leerink Global Healthcare Conference

BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced that Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals together with other members of the Atea management team, will participate in a fireside chat and provide a business update at the 11th Annual SVB Le

Yahoo | February 9, 2022

Vanguard Capital Wealth Advisors Buys VanEck Gold Miners ETF, ViacomCBS Inc, Uber Technologies ...

Investment company Vanguard Capital Wealth Advisors (Current Portfolio) buys VanEck Gold Miners ETF, ViacomCBS Inc, Uber Technologies Inc, Cleveland-Cliffs Inc, PayPal Holdings Inc, sells iShares Gold Trust, Alibaba Group Holding, iShares 20+ Year Treasury Bond ETF, Coca-Cola Femsa SAB de CV, Pfizer Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Vanguard Capital Wealth Advisors.

Yahoo | February 2, 2022

Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ...

Investment company Emerald Advisers, Llc (Current Portfolio) buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals Inc, HireRight Holdings Corp, Arhaus Inc, sells Chegg Inc, ORIC Pharmaceuticals Inc, BellRing Brands Inc, Trex Co Inc, Arena Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Emerald Advisers, Llc.

Yahoo | February 2, 2022

Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications

Data show bemnifosbuvir’s unique mechanism of action increases barrier for emergence of resistance, making it an ideal candidate for treatment of COVID-19 and for combination therapyBOSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that new data highlighting bemnifosbuvir (AT-527) were published in the peer-reviewed journal, Nature Communications, in an article titled, “A dual mechanism of act

Yahoo | February 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4951 seconds.